A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer
Status:
Active, not recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
This is a Phase II, open-label, multicenter study of Savolitinib administered orally once per
day(QD) to locally advanced/metastatic PSC patients and other NSCLC patients with MET Exon 14
mutation. The targeted population is the patients with MET Exon 14 mutation who have failed
prior systemic therapy (ies), or are unwilling or can not tolerate to receive chemotherapy.
Pathological diagnosis will be confirmed retrospectively by the central pathological
laboratory.